Soleno Therapeutics, Inc. (SLNO) Revenue Tops Expectations With $91.7M in Q4 Results, TD Cowen Maintains Buy [Yahoo! Finance]
Soleno Therapeutics, Inc. (SLNO)
Last soleno therapeutics, inc. earnings: 5/13 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.soleno.life/investor-overview
Company Research
Source: Yahoo! Finance
Therapeutics, Inc. (NASDAQ:SLNO) posted strong financial results for the fourth quarter of 2025, exceeding Wall Street estimates with EPS of $0.80, up from $0.61. Revenue also exceeded expectations, totaling $91.7 million compared to an expected $82.45 million, representing an 11.26% increase. Soleno Therapeutics, Inc. (SLNO) Revenue Tops Expectations With $91.7M in Q4 Results, TD Cowen Maintains Buy Following the earnings report, TD Cowen analyst Tyler Van Buren reduced the price target for Soleno Therapeutics, Inc. (NASDAQ:SLNO) to $85 from $120 while maintaining a Buy rating. According to the firm, Soleno experienced a solid Q4, producing $190 million in revenue from just nine months of Vykat XR sales, and ended 2025 financially viable. Management also maintained a strong commercial trajectory for 2026, with about 1,000 new start forms expected over the next 9-12 months. Soleno Therapeutics, Inc. (NASDAQ:SLNO) is a clinical-stage biopharmaceutical company developing novel t
Show less
Read more
Impact Snapshot
Event Time:
SLNO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLNO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLNO alerts
High impacting Soleno Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SLNO
News
- Soleno Therapeutics (SLNO) had its price target lowered by HC Wainwright from $120.00 to $100.00. They now have a "buy" rating on the stock.MarketBeat
- Wells Fargo Cuts PT on Soleno Therapeutics (SLNO) to $110 From $114 – Here's Why [Yahoo! Finance]Yahoo! Finance
- Soleno Profitability Milestone And CFO Shift Raise Valuation Questions [Yahoo! Finance]Yahoo! Finance
- Soleno Therapeutics, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Soleno Therapeutics (SLNO) had its price target lowered by Wells Fargo & Company from $114.00 to $110.00. They now have an "overweight" rating on the stock.MarketBeat
SLNO
Earnings
- 2/25/26 - Beat
SLNO
Sec Filings
- 3/4/26 - Form 4
- 3/4/26 - Form 3
- 2/26/26 - Form 8-K
- SLNO's page on the SEC website